FN2 Earnings Intelligence
Charles River Laboratories International, Inc. ratios
Charles River Laboratories International, Inc. (CRL) Ratios (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 | 12/27/2026 est. | 12/27/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $241.2 | $233.9 | $276.8 | $194.6 | $213.8 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $3,540.2 | $3,976.1 | $4,129.4 | $4,050 | $4,015.4 | $3,849.8 | $3,918.2 |
| % Growth | 21.1% | 12.3% | 3.9% | -1.9% | -0.9% | -4.1% | 1.8% |
| Gross Profit | $1,702.7 | $1,832.7 | $1,833.4 | $1,704.2 | $1,700.6 | - | - |
| % Margin | 48.1% | 46.1% | 44.4% | 42.1% | 42.4% | - | - |
| EBITDA | $855.4 | $954.8 | $931.4 | $589.1 | $428.5 | - | - |
| % Margin | 24.2% | 24.0% | 22.6% | 14.5% | 10.7% | - | - |
| Net Income | $391 | $486.2 | $474.6 | $22.2 | -$144.3 | - | - |
| % Margin | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% | - | - |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 | $11.11 | $12.35 |
| % Growth | 5.6% | 24.7% | -2.7% | -97.8% | -1,555.0% | 481.6% | 11.2% |
| Operating Cash Flow | $760.8 | $619.6 | $683.9 | $734.6 | $737.6 | - | - |
| CapEx | $228.8 | $324.7 | $318.5 | $233 | $219.2 | - | - |
| Free Cash Flow | $532 | $294.9 | $365.4 | $501.6 | $518.5 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 | 12/27/2026 est. | 12/27/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $3,540.2 | $3,976.1 | $4,129.4 | $4,050 | $4,015.4 | $3,849.8 | $3,918.2 |
| Gross Profit | $1,702.7 | $1,832.7 | $1,833.4 | $1,704.2 | $1,700.6 | - | - |
| EBITDA | $855.4 | $954.8 | $931.4 | $589.1 | $428.5 | - | - |
| Net Income | $391 | $486.2 | $474.6 | $22.2 | -$144.3 | - | - |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 | $11.11 | $12.35 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $241.2 | $233.9 | $276.8 | $194.6 | $213.8 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $760.8 | $619.6 | $683.9 | $734.6 | $737.6 |
| Capital Expenditure | $228.8 | $324.7 | $318.5 | $233 | $219.2 |
| Free Cash Flow | $532 | $294.9 | $365.4 | $501.6 | $518.5 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 21.1% | 12.3% | 3.9% | -1.9% | -0.9% |
| Gross Margin | 48.1% | 46.1% | 44.4% | 42.1% | 42.4% |
| EBITDA Margin | 24.2% | 24.0% | 22.6% | 14.5% | 10.7% |
| Net Margin | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% |
| FCF Margin | 15.0% | 7.4% | 8.8% | 12.4% | 12.9% |
| Diluted EPS Growth | 5.6% | 24.7% | -2.7% | -97.8% | -1,555.0% |